Home > Compound List > Compound details
284028-89-3 molecular structure
click picture or here to close

2-[4-(trifluoromethyl)phenyl]-5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-ol

ChemBase ID: 72563
Molecular Formular: C14H11F3N2OS
Molecular Mass: 312.3101496
Monoisotopic Mass: 312.05441864
SMILES and InChIs

SMILES:
c1cc(ccc1C(F)(F)F)c1nc(c2c(n1)CCSC2)O
Canonical SMILES:
Oc1nc(nc2c1CSCC2)c1ccc(cc1)C(F)(F)F
InChI:
InChI=1S/C14H11F3N2OS/c15-14(16,17)9-3-1-8(2-4-9)12-18-11-5-6-21-7-10(11)13(20)19-12/h1-4H,5-7H2,(H,18,19,20)
InChIKey:
KLGQSVMIPOVQAX-UHFFFAOYSA-N

Cite this record

CBID:72563 http://www.chembase.cn/molecule-72563.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
2-[4-(trifluoromethyl)phenyl]-5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-ol
IUPAC Traditional name
2-[4-(trifluoromethyl)phenyl]-5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-ol
Synonyms
XAV939
XAV-939
CAS Number
284028-89-3
PubChem SID
162037488
PubChem CID
2726824

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price
Selleck Chemicals
S1180 external link Add to cart Please log in.
Data Source Data ID
PubChem 2726824 external link

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem
Acid pKa 12.525094  H Acceptors
H Donor LogD (pH = 5.5) 4.43885 
LogD (pH = 7.4) 4.4388576  Log P 4.438861 
Molar Refractivity 86.678 cm3 Polarizability 28.26515 Å3
Polar Surface Area 46.01 Å2 Rotatable Bonds
Lipinski's Rule of Five true 

PROPERTIES

PROPERTIES

Physical Property Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Solubility
DMSO expand Show data source
Storage Condition
-20°C expand Show data source
Target
Wnt expand Show data source
Salt Data
Free Base expand Show data source

DETAILS

DETAILS

Selleck Chemicals Selleck Chemicals
Selleck Chemicals - S1180 external link
Research Area
Description Cancer
Biological Activity
Description XAV-939 is a selective Wnt β-catenin-mediated transcription inhibitor for TNKS1 and TNKS2 with IC50 of 11 nM and 4 nM, respectively.
Targets TNKS1 TNKS2
IC50 11 nM 4 nM [1]
In Vitro XAV-939 specifically inhibits tankyrase PARP activity. XAV-939 dramatically decreases DNA-PKcs protein levels, confirming the critical role of tankyrase poly-ADP-ribosylation activity in maintaining stability of the DNA-PKcs protein. The greatest reduction of DNA-PKcs protein levels (< 25%="" relative="" expression="" compared="" to="" dmso="" treated="" controls)="" occurs="" at="" 12="" hours="" with="" 1.0="" μm="" xav-939="" exposure.="" treatment="" of="" human="" lymphoblasts="" with="" 1.0="" μm="" xav-939="" results="" in="" marked="" elevation="" of="" tankyrase="" 1="" levels.="">[1] XAV-939 is axin stabilizing agent. XAV-939 stimulates beta-catenin degradation by stabilizing axin, the concentration-limiting component of the destruction complex. XAV-939 stabilizes axin by blocking the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. XAV-939 deregulates the Wnt/b-catenin pathway which has been implicated in many cancers. [2]
In Vivo
Clinical Trials
Features
Protocol
Cell Assay [1]
Cell Lines WTK1 lymphoblasts
Concentrations 1.0 μM
Incubation Time 8 hours
Methods XAV-939 is solubilized in DMSO at 55 °C to make a 10 mM stock solution which may be diluted later to a working concentration of 100 μM. WTK1 lymphoblasts treated with either DMSO or 1.0 μM XAV-939 for 8 hours are loaded into independent wells of a 4-20% gradient SDS-PAGE every 2 hours over the course of 6 hours. At each time point, DMSO and XAV-939 samples are loaded into wells immediately adjacent to the prior time point. The corresponding load times at 0, 2 and 4 hours results in total run times of 2, 4 and 6 hours respectively. The gel is analyzed via western blot for DNA-PKcs following completion of the final run time and is quantified after normalization to actin loading controls.
References
[1] Dregalla RC, et al. Aging, 2010, 2(10), 691-708.
[2] Huang SM, et al. Nature, 2009, 461(7264), 614-620.

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle